Seeking the “mother of blood” from human pluripotent stem cells: Are we there yet?

Induced pluripotent stem cells (iPSCs) hold great promise for the treatment of human diseases, including the failure of bone marrow. Incremental progress across the past three and half decades has brought us closer to making hematopoietic stem cells from iPSCs clinical solutions. A recent innovative...

Descripción completa

Detalles Bibliográficos
Autor principal: Li, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146206/
https://www.ncbi.nlm.nih.gov/pubmed/30258915
http://dx.doi.org/10.1016/j.gendis.2017.07.005
_version_ 1783356359047118848
author Li, Fei
author_facet Li, Fei
author_sort Li, Fei
collection PubMed
description Induced pluripotent stem cells (iPSCs) hold great promise for the treatment of human diseases, including the failure of bone marrow. Incremental progress across the past three and half decades has brought us closer to making hematopoietic stem cells from iPSCs clinical solutions. A recent innovative two-step differentiation approach successfully generated transplantable HSCs from iPSC sources. For clinical translation, the long-term safety of these gene-altered HSCs must be determined.
format Online
Article
Text
id pubmed-6146206
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Chongqing Medical University
record_format MEDLINE/PubMed
spelling pubmed-61462062018-09-26 Seeking the “mother of blood” from human pluripotent stem cells: Are we there yet? Li, Fei Genes Dis Article Induced pluripotent stem cells (iPSCs) hold great promise for the treatment of human diseases, including the failure of bone marrow. Incremental progress across the past three and half decades has brought us closer to making hematopoietic stem cells from iPSCs clinical solutions. A recent innovative two-step differentiation approach successfully generated transplantable HSCs from iPSC sources. For clinical translation, the long-term safety of these gene-altered HSCs must be determined. Chongqing Medical University 2017-07-20 /pmc/articles/PMC6146206/ /pubmed/30258915 http://dx.doi.org/10.1016/j.gendis.2017.07.005 Text en © 2017 Chongqing Medical University. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Li, Fei
Seeking the “mother of blood” from human pluripotent stem cells: Are we there yet?
title Seeking the “mother of blood” from human pluripotent stem cells: Are we there yet?
title_full Seeking the “mother of blood” from human pluripotent stem cells: Are we there yet?
title_fullStr Seeking the “mother of blood” from human pluripotent stem cells: Are we there yet?
title_full_unstemmed Seeking the “mother of blood” from human pluripotent stem cells: Are we there yet?
title_short Seeking the “mother of blood” from human pluripotent stem cells: Are we there yet?
title_sort seeking the “mother of blood” from human pluripotent stem cells: are we there yet?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146206/
https://www.ncbi.nlm.nih.gov/pubmed/30258915
http://dx.doi.org/10.1016/j.gendis.2017.07.005
work_keys_str_mv AT lifei seekingthemotherofbloodfromhumanpluripotentstemcellsarewethereyet

Ejemplares similares